Hyperliquid Strategies Inc - Common Stock (PURR)
10.97
+0.10 (0.92%)
NASDAQ· Last Trade: Jun 3rd, 1:55 AM EDT
Detailed Quote
| Previous Close | 10.87 |
|---|---|
| Open | 10.86 |
| Bid | 10.53 |
| Ask | 10.59 |
| Day's Range | 10.27 - 11.29 |
| 52 Week Range | 3.010 - 11.62 |
| Volume | 28,248,760 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 16,010,692 |
Chart
News & Press Releases
Arthur Hayes bet $100,000 that Hyperliquid, as measured by Hyperliquid Strategies Inc (NASDAQ:PURR) outperforms every other top 10 crypto
Via Benzinga · June 2, 2026
A few different players are taking an interest in the network.
Via The Motley Fool · June 1, 2026
The investment bank has clearly had a change of heart regarding which cryptocurrencies it thinks are worth owning.
Via The Motley Fool · May 28, 2026
Coinbase Global and Hyperliquid Strategies are ideally positioned to capture institutional capital as tokenized securities modernize global equity markets.
Via MarketBeat · May 21, 2026
Hyperliquid Strategies (NASDAQ:PURR) reported a profitable fiscal third quarter, with results driven primarily by appreciation in the HYPE token and continued staking revenue, executives said on the company’s third-quarter 2026 earnings call.
CEO David Schamis said the company remains “by far the l
Via MarketBeat · May 8, 2026
This is an important decision if you want exposure to the growth of crypto derivatives.
Via The Motley Fool · May 2, 2026
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · April 10, 2026
Hyperliquid’s (NASDAQ:PURR) oil perpetual futures contract hit $1.7 billion in daily trading volume as non-crypto traders sought 24/7 oil exposure during the Iran war
Via Benzinga · March 19, 2026
BitMEX co-founder Arthur Hayes says he has re-entered his Hyperliquid (NASDAQ:PURR) trade, predicting the asset could surge more than fourfold if the p
Via Benzinga · March 16, 2026
As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale . While most investor focus remains on drug developers, ENDRA Life Sciences (NASDAQ: NDRA) is positioning itself on the infrastructure side of the emerging MASH ecosystem with its innovative TAEUS® (Thermo-Acoustic Enhanced UltraSound) liver imaging technology.
Via AB Newswire · March 9, 2026